Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial

Autor:	Popat, Uday R, Mehta, Rohtesh S, Bassett, Roland, Chen, Julianne, Valdez, Benigno C, Kawedia, Jitesh, Ahmed, Sairah, Alousi, Amin M, Anderlini, Paolo, Al-Atrash, Geath, Bashir, Qaiser, Ciurea, Stefan O, Hosing, Chitra M, Im, Jin S, Jones, Roy, Kebriaei, Partow, Khouri, Issa, Marin, David, Nieto, Yago, Olson, Amanda, Oran, Betul, Parmar, Simrit, Rezvani, Katayoun, Qazilbash, Muzaffar H, Shah, Nina, Srour, Samer A, Shpall, Elizabeth J, Champlin, Richard E, Andersson, Borje S
Zdroj:	In The Lancet Haematology November 2018 5(11):e532-e542
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu